Last updated: February 13, 2026
Overview
NDC 70710-1025 corresponds to Emtricitabine and Tenofovir Disoproxil Fumarate, a combination medication used in antiretroviral therapy for HIV. The drug plays a significant role in HIV management and has been a standard component of treatment guidelines worldwide.
Market Dynamics
-
Global Market Size: The HIV therapeutics market was valued at approximately $21 billion in 2022, with antiretroviral drugs accounting for around 80% of this figure ([1]). Emtricitabine/Tenofovir disoproxil fumarate (FTC/TDF) holds a substantial portion, primarily in North America, Europe, and select Asia-Pacific markets.
-
Market Share & Competitive Landscape:
- Brand Drugs: Gilead Sciences' Truvada and Descovy dominate the FTC/TDF segment. Truvada alone generated nearly $3.9 billion in 2022 sales globally ([2]).
- Generics: As patents expire, generic formulations threaten to reduce brand market share; however, some formulations remain under patent protection or exclusivity periods in certain regions.
-
Key Drivers:
- Increasing adoption in pre-exposure prophylaxis (PrEP) for HIV prevention.
- Growing access to treatment in low- and middle-income countries, supported by global health initiatives.
- Official guideline recommendations from agencies like the CDC and WHO promote early and sustained antiretroviral therapy.
-
Regulatory & Policy Factors:
- Patent expirations scheduled for 2024-2026 for some formulations in the U.S. ([3]).
- Price reductions driven by generic competition and voluntary licensing agreements.
- Moves toward fixed-dose combinations improve adherence and market penetration.
Price Projections
| Scenario |
2023 Price (USD) per 30-day supply |
2025 Price (USD) per 30-day supply |
Notes |
| Brand (Truvada/Descovy) |
$1,800 – $2,200 |
$1,500 – $1,800 |
Prices vary by payer, region, and insurance |
| Generic (post-patent expiry) |
$300 – $500 |
$200 – $400 |
Widespread availability expected in 2024-2026 |
| PrEP-specific formulations |
$1,200 – $1,800 |
$1,000 – $1,500 |
Market expansion expected to influence pricing |
-
Market Entry Impact:
- Generic versions could reduce prices by up to 80% within two years of patent expiry ([4]).
- Price reductions are more significant in regions with national formularies and government price controls.
-
Pricing Trends:
- Continued shift toward lower-cost generics will exert downward pressure on brand prices.
- Larger payers and government programs negotiate discounts, influencing public sector pricing.
Revenue and Volume Trends
- U.S. Market: The market for FTC/TDF in the U.S. remains robust, with annual sales estimated at $4-5 billion, driven by both treatment and PrEP.
- Emerging Markets: Outreach in Africa, Southeast Asia, and Latin America boosts volume but at lower unit prices.
- Market Saturation: The high prevalence of HIV and expanding access to PrEP and treatment sustain steady demand.
Risks and Opportunities
- Patent litigations could delay generic entry or extend exclusivity.
- The advent of new therapies, such as long-acting injectables (e.g., cabotegravir), could reduce demand for daily oral regimens.
- Generic availability offers a competitive opportunity but also pressures margins of branded drugs.
Key Takeaways
- The drug currently commands high prices in branded form, with significant volume in North America and Europe.
- Patent expiries slated for 2024–2026 will likely trigger substantial price reductions associated with generic versions.
- Market growth depends on global HIV/AIDS treatment programs and PrEP adoption.
- Price declines are expected as generic competition intensifies, especially in low-to-middle-income countries.
- Remaining patent protections and potential new formulations could influence future pricing stability or volatility.
FAQs
1. When will generic versions of NDC 70710-1025 become widely available?
Patent expiries in the U.S. are scheduled for 2024–2026, enabling generic manufacturers to enter the market.
2. How much could prices drop after patent expiry?
Prices could decline by up to 80% within two years of patent expiration, especially in markets with strong generic competition.
3. Which markets will see the fastest price reductions?
Regions with established generic manufacturing infrastructure, such as India and China, will see earlier and larger price reductions.
4. Will new formulations or delivery methods affect this drug's market?
Yes. Long-acting injectables and alternative regimens are emerging, potentially reducing reliance on daily oral pills.
5. How does global policy impact pricing?
Government procurement policies, pricing negotiations, and licensing agreements significantly influence the final consumer and institutional prices.
Citations
[1] MarketWatch. "HIV Therapeutics Market Size." 2022.
[2] Gilead Sciences. Annual Report 2022.
[3] U.S. Patent and Trademark Office. Patent expiry schedules.
[4] IMS Health. "Impact of Patent Expirations on HIV Drug Pricing," 2021.
